JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The Purpose of this trial is:

• to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL
• to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Inclusion Criteria:

• relapsed or refractory HL
• ECOG <= 2,
• no major organ dysfunction
• written informed consent

Exclusion Criteria:

• history of another primary malignancy ≤ 2 years
• female patients who are pregnant or breast feeding
• patients with a known history of HIV seropositivity
• chronic active hepatitis